RheumaGen
Denver, US · Founded 2022 · Delaware corporation
RheumaGen is a private biotechnology company developing one-time cell and gene therapies that edit the human leukocyte antigen (HLA) to treat autoimmune diseases at their source. It works with the University of Colorado Anschutz Medical Campus and its ClinImmune laboratory to advance clinical programs.
Founders & leadership
RheumaGen was founded in 2022 by Richard Freed, Brian Hart, and Brian Freed.
RF
Richard FreedinCEO & Co-Founder
BH
Brian HartinCOO & Co-Founder
BF
Brian FreedChief Science Officer & Co-Founder
RH
Ryan HartChief Business and Legal Officer
TH
Tate HermansoninVice President, Finance
BR
B Robert MozayeniinChief Medical Officer
JB
James Brian Hart, Jr.Named on SEC filing
GL
Gregory L. AndrewsNamed on SEC filing
RA
Richard Anthony Freed, IIINamed on SEC filing
Reported raises · per SEC filings
Form D private placements$7.9M disclosed across 4 rounds · 2022–2024
▶$4.9MraisedApr 2024 · 3 investors · BiotechnologyRule 506(b)
▶$4.9MraisedApr 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan Kane HartExecutive Officer
- Bobak Robert MozayeniExecutive Officer
- Bruce Michael GoodwinDirector
- Thomas FratacciDirector
- Brian Matthew FreedExecutive Officer
- Richard Anthony Freed, IIIExecutive Officer, Director
- James Brian Hart, Jr.Executive Officer
- Offering amount
- $15M
- Amount sold
- $4.9M
- Proceeds to insiders
- $3M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$700KraisedApr 2024 · 1 investors · BiotechnologyRule 506(b)
▶$700KraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce Michael GoodwinDirector
- James Brian Hart, Jr.Executive Officer
- Bobak Robert MozayeniExecutive Officer
- Ryan Kane HartExecutive Officer
- Thomas FratacciDirector
- Brian Matthew FreedExecutive Officer
- Richard Anthony Freed, IIIExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$300KraisedMay 2023 · 1 investors · BiotechnologyRule 506(b)
▶$300KraisedMay 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Brian Hart, Jr.Executive Officer
- Brian M. FreedExecutive Officer, Director
- Gregory L. AndrewsDirector
- Richard Anthony Freed, IIIExecutive Officer, Director
- Ryan Kane HartExecutive Officer
- Offering amount
- $300K
- Amount sold
- $300K
- Minimum investment
- $300K
- Proceeds to insiders
- $243.7K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$2MraisedOct 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Brian Hart, Jr.Executive Officer
- Ryan Kane HartExecutive Officer
- Gregory L. AndrewsDirector
- Richard Anthony Freed, IIIExecutive Officer, Director
- Brian M. FreedExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $2M
- Proceeds to insiders
- $970.2K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Biogen Idec18 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Amgen Europe12 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
NervGen Pharma10 shared keywordsNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Urogen9 shared keywordsUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
Thumbnail for Seragon Pharmaceuticals9 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
PepGen9 shared keywordsPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Regeneron NASDAQ: REGN www.regeneron.com8 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies competing with RheumaGen for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does RheumaGen do?
- RheumaGen is a private biotechnology company developing one-time cell and gene therapies that edit the human leukocyte antigen (HLA) to treat autoimmune diseases at their source. It works with the University of Colorado Anschutz Medical Campus and its ClinImmune laboratory to advance clinical programs.
- Who founded RheumaGen?
- RheumaGen was founded by Richard Freed, Brian Hart, Brian Freed in 2022.
- How much funding has RheumaGen raised?
- RheumaGen has disclosed $7.9M raised across 4 rounds.
- Where is RheumaGen headquartered?
- RheumaGen is headquartered in Denver, US.